Company: ABUS
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012305
Chunk: 16

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 16
---
 desires. Information regarding the fees paid to our independent registered public accounting firm in 2024 and 2023 and our pre-approval policies relating to such fees is discussed in the “Independent Registered Public Accounting Firm”section of this Proxy Statement/Circular. Vote Required and Recommendation of our Board The approval of this Proposal No. 3 requires a majority of the votes cast at the Annual Meeting. For purposes of determining the number of votes cast, only the Common Shares voting “FOR” or “AGAINST” will be counted. Our Board recommends that our Shareholders vote FOR the approval of the appointment of EY as our independent registered public accounting firm for the fiscal year ending December 31, 2025. OTHER BUSINESS If any other matters are properly presented for consideration at the Annual Meeting, including, among other things, consideration of a motion to adjourn the Annual Meeting to another time or place in order to solicit additional proxies in favor of the recommendation of our Board, the designated proxyholders intend to vote the shares represented by the proxies appointing them on such matters in accordance with the recommendation of our Board, and the authority to do so is included in the proxy. As of the date of this Proxy Statement/Circular, our Board knows of no other matters which are likely to come before the Annual Meeting. 9

TABLE OF CONTENTS

EXECUTIVE OFFICERS AND DIRECTORS Board Composition Our Board currently consists of five (5) directors. The term of office of each of the current directors will end immediately before the election of directors at the Annual Meeting. Unless the director’s office is earlier vacated in accordance with the provisions of the BCBCA and our Articles, each director elected will hold office until immediately before the election of new directors at the next annual general meeting of our Shareholders and, if no director is then elected, until a qualified successor is duly elected or appointed. Executive Officers and Director Nominees Our executive officers and director nominees, their positions with the Company and their ages as of March 28, 2025, are as follows:

| Name                            |     | Age |     | Position(s)                                                         |
| Lindsay Androski, JD, MBA, CFA* |     |  48 |     | President and Chief Executive Officer, and Chairperson of the Board |
| Tuan Nguyen                     |     |  49 |     | Chief Financial Officer                                             |
| Robert Alan Beardsley*+†        |     |  64 |     | Director                                                            |
| Joseph Bishop